SELLAS to Host Corporate Update Call on January 8, 2025, at 9:00 am ET
MWN-AI** Summary
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS), a late-stage clinical biopharmaceutical company focused on innovative cancer therapies, will host a corporate update call on January 8, 2025, at 9:00 a.m. Eastern Time. During this call, Angelos Stergiou, MD, ScD h.c., President and CEO, will provide insights into the Company’s strategic outlook for 2025. He will be joined by Dr. Yair Levy, Director of Hematologic Malignancies at Baylor University Medical Center, who is also a member of the REGAL Steering Committee.
The update will likely highlight the progress of SELLAS’ lead product candidate, GPS, which targets the WT1 protein present in various tumor types, making it a promising option for both monotherapy and combination treatments across hematologic malignancies and solid tumors. Additionally, the company is advancing SLS009 (formerly GFH009), a potentially first-in-class CDK9 inhibitor known for its reduced toxicity and enhanced potency, particularly in treating acute myeloid leukemia (AML) patients with adverse prognostic factors.
SELLAS emphasizes the inherent risks and uncertainties in oncology product development, including regulatory approval challenges and clinical success rates. The outcome of their initiatives, including the GPS clinical program and REGAL study, will be key topics in the discussion.
Investors and interested parties can access the webinar for a deeper understanding of SELLAS’ future endeavors and milestones. Further details can be found on the Company’s website at www.sellaslifesciences.com.
This update demonstrates SELLAS' commitment to transparency and engagement as it navigates the complexities of cancer therapeutics development.
MWN-AI** Analysis
As SELLAS Life Sciences Group, Inc. prepares for its corporate update call on January 8, 2025, investors should carefully analyze the implications of the discussion regarding the company's clinical development programs and overall outlook. SELLAS, a late-stage clinical biopharmaceutical company, is at a pivotal junction with its lead product candidate GPS, and SLS009, both of which target significant opportunities in oncology.
The upcoming call, featuring insights from CEO Angelos Stergiou and Dr. Yair Levy, is an opportunity for investors to gauge the commercialization potential of GPS in treating a variety of tumor types by targeting the WT1 protein. Notably, the company's focus on hematologic malignancies and solid tumors could present a diversified portfolio for long-term growth, especially as GPS functions both as a monotherapy and in combination treatments.
Particular attention should be paid to updates regarding the REGAL study and other ongoing clinical trials, as successful data readouts are critical for regulatory approval and future market potential. Investors will want to be wary of the inherent risks outlined in previous communications, especially regarding oncology product development, which can be fraught with uncertainties.
Additionally, the promising results of SLS009, particularly among AML patients with adverse prognostic factors, highlight a potentially transformative product that could address unmet medical needs in the market. The implications of a first-in-class CDK9 inhibitor with better toxicity profiles could position SELLAS competitively against more established players.
In summary, while there could be volatility in SELLAS stock as insights are shared during the call, a thoughtful long-term investment strategy focusing on the clinical milestones, market entry for their drug candidates, and the broader trends in oncology treatments will be vital. Monitoring regulatory progresses and market reactions post-announcement will be crucial to navigate this evolving growth opportunity.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it will host a corporate update call on Wednesday, January 8, 2025, at 9:00 a.m. Eastern Time.
Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS, will discuss the Company’s outlook for 2025 and will be joined by Dr. Yair Levy, Director of Hematologic Malignancies at the Baylor University Medical Center, and member of the REGAL Steering Committee.
To access the webinar, please use the following information:
Date: Wednesday, January 8, 2025
Time: 9:00 a.m. Eastern Time
Webcast: 2025 Business Outlook
About SELLAS Life Sciences Group, Inc.
SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has the potential as a monotherapy and combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing SLS009 (formerly GFH009) - potentially the first and best-in-class differentiated small molecule CDK9 inhibitor with reduced toxicity and increased potency compared to other CDK9 inhibitors. Data suggests that SLS009 demonstrated a high response rate in AML patients with unfavorable prognostic factors including ASXL1 mutation, commonly associated with poor prognosis in various myeloid diseases. For more information on SELLAS, please visit www.sellaslifesciences.com.
Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as “plan,” “expect,” “anticipate,” “may,” “might,” “will,” “should,” “project,” “believe,” “estimate,” “predict,” “potential,” “intend,” or “continue” and other words or terms of similar meaning. These statements include, without limitation, statements related to the GPS clinical development program, including the REGAL study and the timing of future milestones related thereto. These forward-looking statements are based on current plans, objectives, estimates, expectations, and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties with oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption “Risk Factors” in SELLAS’ Annual Report on Form 10-K filed on March 28, 2024 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS’ forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations, or other circumstances that exist after the date as of which the forward-looking statements were made.
Investor Contact
Bruce Mackle
Managing Director
LifeSci Advisors, LLC
SELLAS@lifesciadvisors.com
Media Contact
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com
FAQ**
What key updates regarding the GPS clinical development program will SELLAS Life Sciences Group Inc. SLS share during the January 8, 2025 corporate update call?
How does SELLAS Life Sciences Group Inc. SLS plan to address the significant risks and uncertainties outlined in its 10-K filing related to oncology product development?
Can SELLAS Life Sciences Group Inc. SLS provide insights on the role of Dr. Yair Levy in the REGAL study and how his input may influence the company's future strategies?
What are SELLAS Life Sciences Group Inc. SLS's expectations for the regulatory approval timeline of its lead product candidate, GPS, in 2025?
**MWN-AI FAQ is based on asking OpenAI questions about SELLAS Life Sciences Group Inc. (NASDAQ: SLS).
NASDAQ: SLS
SLS Trading
1.87% G/L:
$7.10 Last:
2,020,090 Volume:
$7.16 Open:
